Tevogen Inc. (TVGN) Current Ratio
- Current ratio · latest quarter: Value 0.33×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 0.33× | Current assets / current liabilities. $2.01M ÷ $6.15M ≈ 0.33× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 2.01M USD | Assets, Current |
| Current obligations | 6.15M USD | Liabilities, Current |
| Cash and equivalents | (m) | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 2.83M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.01M | $6.15M | (m) | (m) | (m) | (m) | $2.83M | (m) | 0.33× |
| 2026-03-31 | $2.14M | $7.27M | (m) | (m) | (m) | (m) | $3.80M | (m) | 0.29× |
| 2025-12-31 | $1.54M | $7.07M | (m) | (m) | (m) | (m) | $3.34M | (m) | 0.22× |
| 2025-09-30 | $2.12M | $6.74M | (m) | (m) | (m) | (m) | $3.31M | (m) | 0.31× |
| 2025-06-30 | $2.06M | $8.08M | (m) | (m) | (m) | (m) | $4.24M | (m) | 0.25× |
| 2025-03-31 | $3.08M | $8.72M | (m) | (m) | (m) | (m) | $4.66M | (m) | 0.35× |
| 2024-12-31 | $2.36M | $9.04M | $0.00 | (m) | (m) | (m) | $5.20M | (m) | 0.26× |
| 2024-09-30 | $3.53M | $10.42M | (m) | (m) | (m) | (m) | $5.84M | (m) | 0.34× |
| 2024-06-30 | $2.45M | $10.61M | (m) | (m) | (m) | (m) | $6.67M | (m) | 0.23× |
| 2024-03-31 | $2.40M | $8.94M | (m) | (m) | (m) | (m) | $5.21M | (m) | 0.27× |
| 2023-12-31 | $1.72M | $85.48M | $0.00 | (m) | (m) | (m) | $3.42M | (m) | 0.02× |
| 2023-09-30 | $399.47K | $1.83M | $25.00M | (m) | (m) | (m) | (m) | (m) | 0.22× |
| 2023-06-30 | $699.33K | $1.52M | $25.00M | (m) | (m) | (m) | (m) | (m) | 0.46× |
| 2023-03-31 | $97.06K | $667.07K | (m) | (m) | (m) | (m) | (m) | (m) | 0.15× |
| 2022-12-31 | $274.36K | $350.45K | (m) | (m) | (m) | (m) | (m) | (m) | 0.78× |
| 2022-09-30 | $418.47K | $281.78K | $143.05K | (m) | (m) | (m) | (m) | (m) | 1.49× |
| 2022-06-30 | $594.75K | $259.23K | $185.65K | (m) | (m) | (m) | (m) | (m) | 2.29× |
| 2022-03-31 | $734.16K | $179.00K | $231.55K | (m) | (m) | (m) | (m) | (m) | 4.10× |
| 2021-12-31 | $791.19K | $59.38K | $344.58K | (m) | (m) | (m) | (m) | (m) | 13.33× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B |